<DOC>
	<DOCNO>NCT03105349</DOCNO>
	<brief_summary>This phase 4 clinical trial treat patient fail treat regimen base inhibitor NS5A</brief_summary>
	<brief_title>A Clinical Trial 16 Weeks Duration Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir Ribavirin Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed Treat With Regime Based Inhibitor NS5A</brief_title>
	<detailed_description>The duration treatment 16 week security perid 2 visit ( Week 12 post treatment week 24 post treatment ) The study open label study single arm .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Adults chronic HCV genotype 1 , 4 infection without HIV infection age 18 year HCV RNA plasma concentration least 1000 IU / mL Subjects previously treat NS5Abased regimen least 8 week . Patients HCV relapse receive complete treatment NS5Abased AAD regimen least 8 week become undetectable end treatment . Relapse define confirm HCV RNA detectable upon completion therapy A5 base NS5A HCV . Subjects compensate hepatic cirrhosis ( Child A ) could include . For patient HIV coinfection : Be infect HIV1 , document rapid HIV test correspond license confirm Western blot second antibody test use method initial rapid HIV / I / CIA method HIV1 p24 antigen viral load HIV1 RNA plasma . Be stable HIV antiretroviral therapy ( ART ) least 4 week prior entry study use dual ITN backbone tenofovir abacavir emtricitabine lamivudine PLUS raltegravir dolutegravir rilpivirine ( CD4 + T cell count &gt; 100 cell / mm 3 undetectable HIV1 RNA baseline . Results prior analysis accept within 24 week prior study entry ) . Subjects hepatitis C steatosis . Subjects previously treat less 8 week regimen base NS5A . Evidence previous hepatocellular carcinoma although criterion cure Subjects past current decompensated liver disease ; Only decompensated patient receive liver transplant decompensated transplantation include . Subjects suspect clinical genotypic reinfection HCV . Subject HCV response regrowth receive NS5Abased ADA therapy HCV . Said regrowth define confirmation detectable HCV RNA achieve undetectable HCV RNA NS5Abased AADs HCV . Recent history drug alcohol abuse . Important comorbidities . Pregnant , lactate nonlactating woman Contraceptives , woman childbearing age . Women childbearing age define woman undergone permanent infertility procedure amenorrheic less 12 month . Subjects glomerular filtration rate le 30 ml / min .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>